CTOs on the Move

CytoDyn

www.cytodyn.com

 
CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection. We have one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which prevents viral entry into healthy T-cells by blocking the HIV co-receptor CCR5. The drug candidate is also being tested for other immunological conditions, and has been granted FDA orphan drug status for the treatment of Graft versus Host Disease (GvHD) in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are undergoing bone marrow ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.cytodyn.com
  • 1111 Main Street Suite 660
    Vancouver, WA USA 98660
  • Phone: 360.980.8524

Executives

Name Title Contact Details
Nitya Ray
Chief Technology Officer Profile

Funding

CytoDyn raised $15M on 03/31/2020

Similar Companies

Semler Research Center Pvt.

Semler Research Center Pvt. is a North Hollywood, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pro Med Molded Products Inc

Pro Med Molded Products Inc is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Fortis Life Sciences

Fortis Life Sciences offers word-class reagents, tools, materials, and custom services for our research, diagnostic and therapeutic customers. Learn more here.

Prescos

Prescos is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ambrx

Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. Ambrx is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications. Specifically, ARX517, its proprietary antibody-drug conjugates (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. Ambrx spun out of The Scripps Research Institute in 2003 and has several other product candidates involving ADCs and other aspects of Ambrx`s protein engineering technology.